

Implementation Science Subgroup Meeting  
September 26, 2018

**Participants:** David Hamer (BU) [co-chair], Karin Kallander (UNICEF) [co-chair], Macie Bayer (USAID), Amy Ginsberg (Save the Children), Elizabeth Hourani (MCSP/JSI), Troy Jacobs (USAID), Dyness Kasungami (MCSP/JSI), Felix Lam (CHAI), Sarah Marks (Malaria Consortium), Alice Maurel (Malaria Consortium), Alfonso Rosales (WVI), Helen Smith (Malaria Consortium), Charlotte Ward (Malaria Consortium), Leslie Wentworth (CHAI)

**Recording Link:** <https://mcsprogram.adobeconnect.com/pynyjdy1mxjj/?proto=true>

**Action Items:**

- Karin to share white papers on pleth device respiratory rate.
- Subgroup members to enter projects into implementation science research mapping document [here](#).
- Subgroup members with active or recently completed research, who would like to present at a future meeting, can email Karin, David, and Elizabeth.
- Felix to forward invite for Melinda Munos' side session at HSR.

**Meeting Notes:**

- Presentation by Charlotte Ward, Malaria Consortium: ARIDA field trials – update on ARIDA device agreement and acceptability studies in Ethiopia and Nepal  
*Due to upcoming presentations at dissemination events, the slides are unable to be shared. Please refer to recording link for additional information.*
- Questions:
  - o Can you explain more about why the Philips ChARM device study was stopped early?
    - It was found halfway through the study that the device showed green when in fact it should have been red. After further investigation, when the reading was on the cutoff (50 vs. 50 or more). The device had to be taken back and reprogrammed and the study could not be continued with those devices.
  - o If in the end the accuracy was not able to be assessed, then what can we say about accuracy at this point?
    - There were a lot of opinions about what we can and cannot say about the results. The advisory group agreed that the message is because we don't have a gold standard at this point, we should not be talking about accuracy of these devices.
  - o Do you have an idea on what the cost would be for these devices?
    - The ChARM device comes in two versions, the rechargeable version is \$75 and the other is \$50. The Rad-G is about \$250.
  - o Will you be doing agreement testing for the Rad-G?
    - This will not be done in the acceptability studies moving forward. This is partly because the partner teams and advisory group do not believe it is worthwhile as there is no reference group to compare it to. Instead, we are looking at consistency in what it was produced to do.
  - o Will you be looking at the time it takes for the Rad-G device to display a respiratory rate?

